SecBot SecBot
8-K ·Filed Nov 6, 2026

CGON

CG Oncology, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed10d 18h ago SEC0001991792-26-000011
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The stock will be driven by upcoming clinical data readouts (PIVOT-006 topline this month, 12-month data in December) and BLA completion timing. Monitor these catalysts for potential inflection; the widening cash burn and EPS miss are already priced into the pre-revenue stage.

DirectionBearish
Confidencehigh
Horizonweeks

cretostimogene

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
Next catalyst
None dated

What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$75.99
T+0 close · Nov 6, 2026 · via day close
Latest settled
−2.09%
T+5 · $74.40
Vs SPY
−4.69%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $75.99entry
  2. T+1 · 8d ago −1.65%α −4.01% · $74.74
  3. T+5 · 4d ago −2.09%α −4.69% · $74.40
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology reported Q3 2026 net loss of $56.9M ($0.64 per share), wider than the $43.8M loss a year ago, and total revenue of $1.6M. The company reiterated its near-term catalysts: PIVOT-006 Phase 3 topline data expected November 2026, 12-month data from two trials in December, and BLA completion for BCG-unresponsive NMIBC in Q4 2026. Cash of $984.5M is sufficient through 2029. The EPS miss versus consensus and widening losses are the headline financial facts.

Key Financial Metrics

EPS
−$0.64
est −$0.81 · +21.0%
Revenue
$1.6M
est $534.0K · +200.4% · -3.7% YoY
Rating
beat

Key Facts

  • Q3 2026 net loss of $56.9M, or $0.64 per share, compared to a net loss of $43.8M, or $0.57 per share, in Q3 2025
  • Total revenue of $1.6M in Q3 2026, flat versus $1.7M in Q3 2025
  • Cash, cash equivalents, and marketable securities of $984.5M as of September 30, 2026, down from $1.0B as of June 30, 2026
  • R&D expenses rose to $39.2M from $27.9M year-over-year, driven by clinical trial and CMC costs
  • PIVOT-006 Phase 3 topline data expected in November 2026; BLA completion for BCG-unresponsive NMIBC expected Q4 2026
  • Appointed Isabel Kalofonos as Chief Commercial Officer in October 2026

Financial Impact

Net loss widened by $13.1M YoY; EPS of $0.64 missed consensus of $0.81 by 21%

net lossepsrevenue

Risk Factors

  • PIVOT-006 topline data may fail to meet efficacy endpoints
  • BLA submission or FDA review could be delayed beyond Q4 2026 guidance
  • Cash burn rate may require future capital raises before reaching profitability

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001991792-26-000011
Document: cgon-20261106.htm0001991792-26-000011
Document: 0001991792-26-000011-index-headers.html0001991792-26-000011
Document: 0001991792-26-000011-index.html0001991792-26-000011
Document: 0001991792-26-000011.txt0001991792-26-000011
8-K Data (Synthetic)0001991792-26-000011

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Viewing Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026